Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

The Food and Drug Administration's approval in 2023 of lecanemab—a novel Alzheimer's therapy shown in clinical trials to ...

No TV before bed. It is poor sleep hygiene to look at screens to scroll or watch a show before bedtime, but what if you ...

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions.

Joint study from MDRF and Washington University reveals loss-of-function ABCC8 mutation as basis for novel MODY subtype ...

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.

Females with AUD are different than men with AUD, but most treatments were tested on men. Researchers are now looking at why ...

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...